BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent

Bergen, 29 October 2025; Reference is made to the joint stock exchangeannouncement made on 24 October 2025 by BerGenBio ASA and Oncoinvent ASA("Oncoinvent") regarding key dates for completion of the combination of thetwocompanies through a statutory triangular merger (the "Merger"). Reference isfurther made to the stock exchange announcement made on 28 October 2025regarding the approval and publication of the prospectus (the "Prospectus")prepared in connection with the Merger and the contemplated rights issue inthecombined company.The last day of trading in the shares of Oncoinvent on Euronext Growth Oslowillbe today, 29 October 2025.

For further details on the timeline for completion of the Merger, please seetheannouncements mentioned above and the Prospectus.

This information is subject to the disclosure requirements pursuant to Section5-12 of the Norwegian Securities Trading Act.About OncoinventOncoinvent is a clinical-stage biotechnology company developing novelradiopharmaceutical therapies against cancer. The lead product candidate,Radspherin®, uses the alpha-emitting radionuclide radium-224, directlytargetingmicro-metastases post-surgery, harnessing the benefits of modernradiopharmaceuticals without the complexities of biological targeting.Oncoinvent is investigating the safety and efficacy of Radspherin® in aclinicaldevelopment program in two indications. One Phase 1 trial and one Phase 1/2atrial have been completed and one randomized Phase 2 trial is currentlyongoingin the US, UK and Europe. Early clinical efficacy data are highly encouraging,and no serious toxicity or safety concerns have been reported to date. TheOncoinvent team consists of approx. 40 employees and runs a state-of-the-artmanufacturing facility to produce drug products for clinical trials inNydalen,Oslo. Oncoinvent is listed on the Euronext Growth Oslo.Forward-looking statement:All statements other than statements of historical facts contained in thispressrelease are forward-looking statements and are not a representation thatOncoinvent's plans, estimates, or expectations will be achieved. These forward-looking statements represent Oncoinvent's expectations as of the date of thispress release, and Oncoinvent disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known andunknown risks and uncertainties that may cause actual results to differmaterially, including with respect to whether the results of clinical or otherstudies will support the use of our product offerings, the impact of resultsofsuch studies, our expectations of the reliability, accuracy and performance ofour tests, or of the benefits of our tests and product offerings to patients,providers and payers.

https://newsweb.oslobors.no/message/658168